Relative Bioavailability Study of Phase III Tablet Formulation of Cabotegravir
This study is a single-center, randomized, open-label, two cohorts, 3-way cross-over design
in 36 subjects to assess the oral bioavailability of four new cabotegravir (CAB) sodium salt
tablet formulations relative to the current CAB sodium salt formulation being used in the
phase IIb studies under fasting conditions. All treatments will be administered as single 30
mg doses of CAB. Safety evaluations and serial PK samples will be collected during each
treatment period. A follow-up visit will occur 10 - 14 days after the last dose of study
drug. Treatment period doses will be separated by a 14 day washout. Participation in this
study will be approximately 12 weeks.
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.